BiotechTube

Perampanel + Standard of Care

Phase 1/2Completed
0 watching 0 views this week⚡ Active
41
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Glioma, Malignant

Conditions

Glioma, Malignant, Surgery, Seizures

Trial Timeline

Nov 5, 2020 → May 16, 2023

NCT ID
NCT04497142

About Perampanel + Standard of Care

Perampanel + Standard of Care is a phase 1/2 stage product being developed by Eisai for Glioma, Malignant. The current trial status is completed. This product is registered under clinical trial identifier NCT04497142. Target conditions include Glioma, Malignant, Surgery, Seizures.

Hype Score Breakdown

Clinical
13
Activity
8
Company
10
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT04497142Phase 1/2Completed

Competing Products

20 competing products in Glioma, Malignant

See all competitors
ProductCompanyStageHype Score
TemozolomideNovocurePhase 1
28
Enzastaurin (LY317615) + CarboplatinEli LillyPhase 1
33
LY2157299 + LomustineEli LillyPhase 1
33
DS-1001bDaiichi SankyoPhase 2
52
DS-1001bDaiichi SankyoPhase 1
33
Temozolomide and BevacizumabEisaiPhase 2
52
TemozolomideEisaiPhase 2
52
Gliadel Wafer + TemozolomideEisaiPhase 2
52
Palonosetron (PALO)EisaiPhase 2
52
Gliadel/Avastin/CPT-11EisaiPhase 2
52
Lenvatinib + BevacizumabEisaiPhase 2
52
Granisetron + OndansetronKyowa KirinPhase 2
52
Binimetinib 15 MGOno PharmaceuticalPhase 2
52
EnzastaurinEli LillyPhase 2
52
Pembrolizumab + Pemetrexed + AbemaciclibEli LillyPhase 1
33
LY2157299 + Radiation + TemozolomideEli LillyPhase 1/2
41
Abemaciclib + TemozolomideEli LillyPhase 2
52
DSP-0390Sumitomo PharmaPhase 1
33
DSP-0390Sumitomo PharmaPhase 1
33
ApatinibJiangsu Hengrui MedicinePhase 2
52

Other Products from Eisai

MecobalaminApproved
85
MonteplaseApproved
85
E2020 + PlaceboApproved
85
Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVApproved
85
DonepezilApproved
85